EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation

Benjamin E Ueberroth, Christopher H Lieu, Robert W Lentz

Journal of Gastrointestinal Cancer · 2024

DOI: 10.1007/s12029-024-01072-0 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of Gastrointestinal Cancer, 2024. Verfasst von Benjamin E Ueberroth und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, 12801 E 17th Ave, MS 8117, Aurora, CO, 80045, USA. b…. Hauptthemen laut MEDLINE: Imidazoles, Oximes, Proto-Oncogene Proteins B-raf, Pancreatic Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Treatment of metastatic pancreatic neuroendocrine tumors (pancNETs), particularly grade 2 (G2) and grade 3 (G3), often presents a dilemma in choosing from multiple similarly efficacious therapies. Data on targeted therapies for these tumor types is limited, and this report presents BRAF-targeted therapy as a therapeutic option for metastatic pancNET G3.

Methods

This is a case report of a patient with G3 pancNET metastatic to the liver, lung, lymph node, and scalp (soft tissue) treated with dabrafenib/trametinib (D/T) in the presence of a BRAF V600E mutation detected in tumor tissue.

Results

This patient has demonstrated an ongoing partial response to therapy at all involved sites for nearly 15 months with minimal side effects attributable to D/T.

Conclusion

Dabrafenib/trametinib therapy for BRAF-mutated metastatic pancNETs provides a novel treatment option and, especially in the G3 setting, should be considered a first-line option. Tumor testing for actionable mutations should be undertaken at the time of diagnosis and/or progression to identify novel therapeutic avenues in these rare tumors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImidazolesOximesProto-Oncogene Proteins B-rafPancreatic NeoplasmsPyrimidinonesPyridonesMutationNeuroendocrine TumorsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleMiddle AgedLiver NeoplasmsFemaleNeoplasm GradingTreatment OutcomeLung Neoplasms

Stichwörter der Autor:innen

BRAFCarcinoidGastrointestinalNeuroendocrineTargeted therapy

Substanzen

ImidazolesdabrafenibOximesProto-Oncogene Proteins B-raftrametinibPyrimidinonesBRAF protein, humanPyridones

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, 12801 E 17th Ave, MS 8117, Aurora, CO, 80045, USA. benjamin.ueberroth@cuanschutz.edu.
  • Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, 12801 E 17th Ave, MS 8117, Aurora, CO, 80045, USA.

Zitieren

APA

Ueberroth, B. E., Lieu, C. H., & Lentz, R. W. (2024). Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-024-01072-0

Vancouver

Ueberroth BE, Lieu CH, Lentz RW. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation. Journal of Gastrointestinal Cancer. 2024. doi:10.1007/s12029-024-01072-0

BibTeX
@article{Ueberroth2024,
  author = {Ueberroth, Benjamin E and Lieu, Christopher H and Lentz, Robert W},
  title = {Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation},
  journal = {Journal of Gastrointestinal Cancer},
  year = {2024},
  doi = {10.1007/s12029-024-01072-0}
}
Kostenlos starten →